EC
ADPT icon

Eminence Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Eminence Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-354,666
Closed -$17.2M – 80
2020
Q3 		$17.2M Buy
+354,666
New +$14.9M 0.17% 72

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eminence Capital's ADPT Position: Q4 2020 in Review

Eminence Capital sold out of Adaptive Biotechnologies (ADPT) in Q4 2020, closing a stake of 354,666 shares — an estimated $17.2M sold.

Eminence Capital first reported a position in ADPT in Q3 2020 and held it in 1 quarter. The position peaked at $17.2M in Q3 2020. 250 funds tracked by Wall St. Rank hold ADPT as of Q4 2020.

  • Eminence Capital reported no remaining Adaptive Biotechnologies position as of Q4 2020 after selling out during the quarter.
  • Eminence Capital sold 354,666 Adaptive Biotechnologies shares in Q4 2020, an estimated $17.2M.
  • Eminence Capital first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 1 quarter.
  • Eminence Capital's Adaptive Biotechnologies position peaked at $17.2M in Q3 2020.
  • 250 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2020.

Based on Eminence Capital's 13F filing for Q4 2020, filed 16 Feb 2021.